Novavax shares rise after Q2 revenue beat, 2026 guidance lift
Novavax says Q2 revenue of $56.7 million topped Wall Street consensus and it raised full-year 2026 revenue guidance to $235 million-$275 million, supporting a late-morning stock gain.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.